Skip to main content
Erschienen in: Current Treatment Options in Neurology 2/2015

01.02.2015 | Neurologic Ophthalmology and Otology (RK Shin and D Gold, Section Editors)

Treatment Options for Optic Pathway Gliomas

verfasst von: Reena P. Thomas, MD, PhD, Iris C. Gibbs, MD, FACR, Linda Wei Xu, MD, Lawrence Recht, MD

Erschienen in: Current Treatment Options in Neurology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Opinion statement

Gliomas that affect the optic pathways are for the most part low-grade neoplasms that often, but not always, have good prognoses. Optimal treatment and management of optic pathway gliomas remains unclear and the decision hinges upon several factors including patient age, tumor location, and visual symptoms. We favor a treatment approach that is dependent on the location of tumor within anterior, chiasmal or posterior/hypothalamic visual pathways. In children who are minimally or not symptomatic, we recommend observation rather than early treatment intervention. Most of these patients will have neurofibromatosis type 1 (NF1) based on the natural history and their pilocytic astrocytoma histology. Serial magnetic resonance imaging studies and formal neuro-ophthalmology testing should enable close observation of these patients, with intervention being reserved for when tumor progression results in significant visual loss or proptosis. Chemotherapy is an accepted first line treatment, and a number of effective medications are available, although no agent has proven clearly superior. If progression is accompanied by the complete loss of vision, surgery can be utilized to help alleviate structural issues (ie, proptosis). Minimally symptomatic chiasmal or hypothalamic tumors that arise in the setting of NF1 can also be observed initially because of their favorable prognosis. Children with NF1 and chiasmal or posterior visual tumors who progress either on imaging or clinical grounds (ie, development of significant visual deficits) should be treated first with chemotherapy rather than radiation therapy to minimize the effects on the developing central nervous system. Individuals without NF1 presenting with a chiasmal or hypothalamic mass are candidates for biopsy to determine the underlying pathology of the lesion. Symptomatic patients with pilocytic astrocytoma should first receive chemotherapy. In contrast, other histologies including malignant optic pathway gliomas should be treated similar to other gliomas that occur in other locations with appropriate doses of radiation and chemotherapy.
Literatur
1.••
Zurück zum Zitat Shapey J, Danesh-Meyer HV, Kaye AH. Diagnosis and management of optic nerve glioma. J Clin Neurosci. 2011;18(12):1585–91. Description of clinical history and current treatments for optic nerve gliomas.CrossRefPubMed Shapey J, Danesh-Meyer HV, Kaye AH. Diagnosis and management of optic nerve glioma. J Clin Neurosci. 2011;18(12):1585–91. Description of clinical history and current treatments for optic nerve gliomas.CrossRefPubMed
2.
Zurück zum Zitat Binning MJ, Liu JK, Kestle JR, Brockmeyer DL, Walker ML. Optic pathway gliomas: a review. Neurosurg Focus. 2007;23(5):E2.CrossRefPubMed Binning MJ, Liu JK, Kestle JR, Brockmeyer DL, Walker ML. Optic pathway gliomas: a review. Neurosurg Focus. 2007;23(5):E2.CrossRefPubMed
3.
Zurück zum Zitat Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007;61(3):189–98.CrossRefPubMed Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007;61(3):189–98.CrossRefPubMed
4.
Zurück zum Zitat Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol. 2009;6((1):1–14. quiz 15‒16. Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol. 2009;6((1):1–14. quiz 15‒16.
5.
Zurück zum Zitat Cirak B. Optic nerve glioma. J Neurosurg. 2003;99(2 Suppl):246. author reply 246. Cirak B. Optic nerve glioma. J Neurosurg. 2003;99(2 Suppl):246. author reply 246.
6.
Zurück zum Zitat Dewandel P, Demaerel P. Optic nerve glioma. JBR-BTR. 2001;84(2):61.PubMed Dewandel P, Demaerel P. Optic nerve glioma. JBR-BTR. 2001;84(2):61.PubMed
7.
Zurück zum Zitat Gutmann DH, Listernick R, Ferner RE. Screening for symptomatic optic pathway glioma in children with neurofibromatosis type 1. Eye (Lond). 2011;25(6):818. author reply 818‒9. Gutmann DH, Listernick R, Ferner RE. Screening for symptomatic optic pathway glioma in children with neurofibromatosis type 1. Eye (Lond). 2011;25(6):818. author reply 818‒9.
8.
Zurück zum Zitat Liu GT. Optic gliomas of the anterior visual pathway. Curr Opin Ophthalmol. 2006;17(5):427–31.CrossRefPubMed Liu GT. Optic gliomas of the anterior visual pathway. Curr Opin Ophthalmol. 2006;17(5):427–31.CrossRefPubMed
9.
11.
Zurück zum Zitat Opocher E, Kremer LC, Da Dalt L, et al. Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer. 2006;42(12):1807–16.CrossRefPubMed Opocher E, Kremer LC, Da Dalt L, et al. Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer. 2006;42(12):1807–16.CrossRefPubMed
12.
Zurück zum Zitat Diaz RJ, Laughlin S, Nicolin G, Buncic JR, Bouffet E, Bartels U. Assessment of chemotherapeutic response in children with proptosis due to optic nerve glioma. Childs Nerv Syst. 2008;24(6):707–12.CrossRefPubMed Diaz RJ, Laughlin S, Nicolin G, Buncic JR, Bouffet E, Bartels U. Assessment of chemotherapeutic response in children with proptosis due to optic nerve glioma. Childs Nerv Syst. 2008;24(6):707–12.CrossRefPubMed
13.
Zurück zum Zitat Balcer LJ, Liu GT, Heller G, et al. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol. 2001;131(4):442–5.CrossRefPubMed Balcer LJ, Liu GT, Heller G, et al. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol. 2001;131(4):442–5.CrossRefPubMed
14.
Zurück zum Zitat Kelly JP, Leary S, Khanna P, Weiss AH. Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas. Ophthalmology. 2012;119(6):1231–7.CrossRefPubMed Kelly JP, Leary S, Khanna P, Weiss AH. Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas. Ophthalmology. 2012;119(6):1231–7.CrossRefPubMed
15.
Zurück zum Zitat Campagna M, Opocher E, Viscardi E, et al. Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1. Pediatr Blood Cancer. 2010;55(6):1083–8.CrossRefPubMed Campagna M, Opocher E, Viscardi E, et al. Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1. Pediatr Blood Cancer. 2010;55(6):1083–8.CrossRefPubMed
16.
Zurück zum Zitat Stafford P, Abdelwahab MG, do Kim Y, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond). 2010;10(7):74.CrossRef Stafford P, Abdelwahab MG, do Kim Y, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond). 2010;10(7):74.CrossRef
17.
Zurück zum Zitat Rieger J, Bahr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44(6):1843–52.PubMedCentralPubMed Rieger J, Bahr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44(6):1843–52.PubMedCentralPubMed
18.
Zurück zum Zitat Gururangan S, Fisher MJ, Allen JC, Herndon II JE, Quinn JA, Reardon DA, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007;9(2):161–8.CrossRefPubMedCentralPubMed Gururangan S, Fisher MJ, Allen JC, Herndon II JE, Quinn JA, Reardon DA, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007;9(2):161–8.CrossRefPubMedCentralPubMed
19.
Zurück zum Zitat Laithier V, Grill J, Le Deley MC, Ruchoux MM, Couanet D, Doz F, et al. French Society of Pediatric Oncology. Progression-free survival in children with optic pathway tumors: dependence on age and quality of the response to chemotherapy –results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol. 2003;21(24):4572–8.CrossRefPubMed Laithier V, Grill J, Le Deley MC, Ruchoux MM, Couanet D, Doz F, et al. French Society of Pediatric Oncology. Progression-free survival in children with optic pathway tumors: dependence on age and quality of the response to chemotherapy –results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol. 2003;21(24):4572–8.CrossRefPubMed
20.
Zurück zum Zitat Gutmann DH, Avery R, Ferner RE, Listernick R. Visual function and optic pathway glioma: a critical response. JAMA Ophthalmol. 2013;131(1):120–1.CrossRefPubMed Gutmann DH, Avery R, Ferner RE, Listernick R. Visual function and optic pathway glioma: a critical response. JAMA Ophthalmol. 2013;131(1):120–1.CrossRefPubMed
21.
Zurück zum Zitat Fard MA, Fakhree S, Eshraghi B. Correlation of optical coherence tomography parameters with clinical and radiological progression in patients with symptomatic optic pathway gliomas. Graefes Arch Clin Exp Ophthalmol. 2013;251(10):2429–36.CrossRefPubMed Fard MA, Fakhree S, Eshraghi B. Correlation of optical coherence tomography parameters with clinical and radiological progression in patients with symptomatic optic pathway gliomas. Graefes Arch Clin Exp Ophthalmol. 2013;251(10):2429–36.CrossRefPubMed
22.
Zurück zum Zitat Parsa CF. Why visual function does not correlate with optic glioma size or growth. Arch Ophthalmol. 2012;130(4):521–2.CrossRefPubMed Parsa CF. Why visual function does not correlate with optic glioma size or growth. Arch Ophthalmol. 2012;130(4):521–2.CrossRefPubMed
23.
Zurück zum Zitat Avery RA, Ferner RE, Listernick R, Fisher MJ, Gutmann DH, Liu GT. Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol. 2012;110(1):1–7.CrossRefPubMed Avery RA, Ferner RE, Listernick R, Fisher MJ, Gutmann DH, Liu GT. Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol. 2012;110(1):1–7.CrossRefPubMed
24.
Zurück zum Zitat Taylor T, Jaspan T, Milano G, et al. Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol. 2008;81(970):761–6.CrossRefPubMed Taylor T, Jaspan T, Milano G, et al. Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol. 2008;81(970):761–6.CrossRefPubMed
25.
Zurück zum Zitat Awdeh RM, Kiehna EN, Drewry RD, et al. Visual outcomes in pediatric optic pathway glioma after conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84(1):46–51.CrossRefPubMedCentralPubMed Awdeh RM, Kiehna EN, Drewry RD, et al. Visual outcomes in pediatric optic pathway glioma after conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84(1):46–51.CrossRefPubMedCentralPubMed
26.
Zurück zum Zitat Marwaha G, Macklis R, Singh AD. Radiation therapy: orbital tumors. Dev Ophthalmol. 2013;52:94–101.CrossRefPubMed Marwaha G, Macklis R, Singh AD. Radiation therapy: orbital tumors. Dev Ophthalmol. 2013;52:94–101.CrossRefPubMed
27.
Zurück zum Zitat Xu D, Liu D, Zhang Z, et al. Gamma Knife surgery in the management of orbital tumors. J Neurosurg. 2010;113(Suppl):34–8.PubMed Xu D, Liu D, Zhang Z, et al. Gamma Knife surgery in the management of orbital tumors. J Neurosurg. 2010;113(Suppl):34–8.PubMed
28.
Zurück zum Zitat Stieber VW. Radiation therapy for visual pathway tumors. J Neuroophthalmol. 2008;28(3):222–30.CrossRefPubMed Stieber VW. Radiation therapy for visual pathway tumors. J Neuroophthalmol. 2008;28(3):222–30.CrossRefPubMed
29.
Zurück zum Zitat Combs SE, Schulz-Ertner D, Moschos D, Thilmann C, Huber PE, Debus J. Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. Int J Radiat Oncol Biol Phys. 2005;62:814–9.CrossRefPubMed Combs SE, Schulz-Ertner D, Moschos D, Thilmann C, Huber PE, Debus J. Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. Int J Radiat Oncol Biol Phys. 2005;62:814–9.CrossRefPubMed
30.
Zurück zum Zitat Debus J, Kocagoncu KO, Hoss A, Wenz F, Wannenmacher M. Fractionated stereotactic radiotherapy (FSRT) for optic glioma. Int J Radiat Oncol Biol Phys. 1999;44:243–8.CrossRefPubMed Debus J, Kocagoncu KO, Hoss A, Wenz F, Wannenmacher M. Fractionated stereotactic radiotherapy (FSRT) for optic glioma. Int J Radiat Oncol Biol Phys. 1999;44:243–8.CrossRefPubMed
31.
Zurück zum Zitat Grabenbauer GG, Schuchardt U, Buchfelder M, Rödel CM, Gusek G, Marx M, et al. Radiation therapy of optico-hypothalamic gliomas (OHG)—radiographic response, vision and late toxicity. Radiother Oncol. 2000;54:239–45.CrossRefPubMed Grabenbauer GG, Schuchardt U, Buchfelder M, Rödel CM, Gusek G, Marx M, et al. Radiation therapy of optico-hypothalamic gliomas (OHG)—radiographic response, vision and late toxicity. Radiother Oncol. 2000;54:239–45.CrossRefPubMed
32.
Zurück zum Zitat Tao ML, Barnes PD, Billett AL, Leong T, Shrieve DC, Scott RM, et al. Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome. Int J Radiat Oncol Biol Phys. 1997;39(3):579–87.CrossRefPubMed Tao ML, Barnes PD, Billett AL, Leong T, Shrieve DC, Scott RM, et al. Childhood optic chiasm gliomas: radiographic response following radiotherapy and long-term clinical outcome. Int J Radiat Oncol Biol Phys. 1997;39(3):579–87.CrossRefPubMed
33.
Zurück zum Zitat Fuss M, Hug EB, Schaefer RA, Nevinny-Stickel M, Miller DW, Slater JM, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique. Int J Radiat Oncol Biol Phys. 1999;45(5):1117–26.CrossRefPubMed Fuss M, Hug EB, Schaefer RA, Nevinny-Stickel M, Miller DW, Slater JM, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique. Int J Radiat Oncol Biol Phys. 1999;45(5):1117–26.CrossRefPubMed
34.
Zurück zum Zitat Han SR, Kim KN, Yee GT, Choi CY, Lee DJ, Sohn MJ, et al. Fractionated stereotactic radiotherapy using Novalis for confined intra-orbital optic nerve glioma in pediatric patient. Childs Nerv Syst. 2013;29(5):867–71.CrossRefPubMed Han SR, Kim KN, Yee GT, Choi CY, Lee DJ, Sohn MJ, et al. Fractionated stereotactic radiotherapy using Novalis for confined intra-orbital optic nerve glioma in pediatric patient. Childs Nerv Syst. 2013;29(5):867–71.CrossRefPubMed
35.•
Zurück zum Zitat Avery RA, Hwang EI, Jakacki RI, Packer RJ. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol. 2014;132(1):111–4. Highlights the use of bevacizumab as a new treatment optic pathway gliomas.CrossRefPubMed Avery RA, Hwang EI, Jakacki RI, Packer RJ. Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol. 2014;132(1):111–4. Highlights the use of bevacizumab as a new treatment optic pathway gliomas.CrossRefPubMed
Metadaten
Titel
Treatment Options for Optic Pathway Gliomas
verfasst von
Reena P. Thomas, MD, PhD
Iris C. Gibbs, MD, FACR
Linda Wei Xu, MD
Lawrence Recht, MD
Publikationsdatum
01.02.2015
Verlag
Springer US
Erschienen in
Current Treatment Options in Neurology / Ausgabe 2/2015
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-014-0333-2

Weitere Artikel der Ausgabe 2/2015

Current Treatment Options in Neurology 2/2015 Zur Ausgabe

Pediatric Neurology (R Boustany, Section Editor)

Current Treatment and Management of Pyridoxine-Dependent Epilepsy

Critical Care Neurology (K Sheth, Section Editor)

Management of Acute Traumatic Spinal Cord Injury

Neurologic Ophthalmology and Otology (RK Shin and D Gold, Section Editors)

Vision Concerns After Mild Traumatic Brain Injury

Critical Care Neurology (K Sheth, Section Editor)

Decompressive Craniectomy in Neurocritical Care

Cerebrovascular Disorders (H Adams, Section Editor)

Imaging Selection for Reperfusion Therapy in Acute Ischemic Stroke

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.